Form 4: Oric Pharmaceuticals Director Acquires Stock Options

Director Richard A. Heyman acquired stock options in Oric Pharmaceuticals, Inc. on June 12, 2024.

Summary

• Richard A. Heyman, a director of Oric Pharmaceuticals, Inc., acquired stock options on June 12, 2024.
• The stock options grant the right to buy 25,600 shares of common stock at an exercise price of $7.90.
• The options vest on the earlier of June 12, 2025, or the business day prior to the next annual meeting of the Issuer's stockholders following the grant date.
• Following the transaction, Heyman directly owns 25,600 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the transaction itself is neither overwhelmingly positive nor negative. It reflects standard executive compensation practices.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it may signal confidence in the company's future.

Key Dates